Amgen said on Wednesday that it’s so no link between its experimental weight-loss drug, MariTide, and changes in bone density, a day after those potential safety concerns knocked greater than $12 billion off its market value.

The company's shares fell greater than 7% on Tuesday as analysts examined data on bone density loss from an early trial of the shot. An analyst said the extra data suggests a brand new potential safety risk related to the drug. But others said the stock move was an overreaction and that more data on a bigger patient population was needed.

In an announcement Wednesday, Amgen said: “The Phase 1 trial results do not indicate any bone safety concerns or change our belief in the promise of MariTide.” The drugmaker added that it looks forward to being the primary Phase 2 trial results for the treatment will probably be announced later this 12 months.

Shares of the corporate rose greater than 1% on Wednesday.

The drug is a promising potential competitor in the load loss drug market. It is designed to be taken monthly, relatively than once per week, as is the case with previous injections Novo Nordisk And Eli Lillyand promotes weight reduction in a different way.

Analysts on Tuesday cited additional publicly available data from a Phase 1 trial showing that the best dose of MariTide – 420 milligrams – was related to a loss in bone mineral density of about 4% over a 12-week period. A decrease in bone mineral density means the bones lose calcium and other minerals, making them weaker and increasing the likelihood of fracture.

In a research note, Cantor-Fitzgerald analyst Olivia Brayer called the information a “big unknown” and suggested it may very well be a possible risk related to drugs like MariTide, which work through so-called GIPR antagonism. Amgen's injection blocks a gut hormone receptor called GIP but additionally prompts one other appetite-stimulating hormone called GLP-1.

This is different than Eli Lilly's obesity drug Zepbound, which prompts GIP and GLP-1. Wegovy prompts GLP-1 but doesn’t goal GIP, which can even affect how the body breaks down sugar and fat.

“On the one hand, patients may naturally lose bone mineral density during weight loss treatment,” Brayer wrote.

But Brayer said, “On the other hand, this could be a failure because there appears to be a dose-dependent increase” in bone mineral density loss. This implies that the upper the dose patients take, the more bone mineral density they seem to lose.

Meanwhile, Jefferies analyst Michael Yee wrote in a note that the extra MariTide data appears to be “a non-issue.” Yee acknowledged that there was a decrease in bone density in individuals who took the best dose of the drug, but said, “The data is patchy.”

For example, he pointed to data on a lower dose of the drug that showed bone density actually increased by 1% before normalizing. Yee added that “changes” in bone mineral density are a known side effect of weight-loss medications in the primary one to a few months of use, as people lose significant weight quickly.

Amgen can be aware of the “hypothetical concern” about lack of bone mineral density, Yee said, citing the corporate's discussions with management.

“While we are of course not saying there is no impact, what we are saying is that we do not believe there is a significant problem.” [bone mineral density] “Overall, we don’t think there is a problem and the effect will normalize over time.”

BMO analyst Evan Seigerman wrote in a note Tuesday: “We would be cautious in making a comprehensive judgment about MariTide's safety profile based on this data.”

He added: “It would be easier for us to assess the safety profile on a larger cohort of patients.” There will not be a transparent answer until Amgen releases full Phase 2 trial data on the drug.

“This has not changed our opinion of MariTide and we consider the sale to be excessive,” Seigerman wrote.

Dental care product provider Heinrich Schein rose in Monday trading as investors bet that Robert F. Kennedy Jr., President-elect Donald Trump's pick as Health and Human Services secretary, could recommend removing fluoride from the U.S. water system, a move that could lead on to a boom would result in dental visits.

Shares of Henry Schein rose about 7.5%, posting their best day since 2022. Co-makers of dental products Dentsply Sirona And Envista also rose within the meeting.

Monday's moves come as investors brace for public health changes under a second Trump administration. kennedy Posted on X ahead of this month's presidential election that a “Trump White House will advise all U.S. water systems to remove fluoride from public water.”

Fluoride has long been proven to be an efficient strategy to combat tooth decay. But the mineral was in the middle of a nationwide fight This has led some local communities to discontinue programs that focused on feeding into public water supplies.

While Kennedy must seek Senate approval to take the job, market participants have already targeted a bunch of stocks that make dental hygiene products as potential beneficiaries of his policies. That's because removing fluoride from water would actually increase demand from the teeth-cleaning industry as consumers look elsewhere to combat tooth decay, in accordance with company Gordon Haskett.

“The idea here is that RFK will give HHS a voice in favor of reducing or eliminating the amount of fluoridation added to drinking water,” Don Bilson, Gordon Haskett's head of event-driven research, told clients in a Monday note. “This in turn will lead to an acceleration in tooth decay and more visits to the dentist.”

Shares of Henry Schein rose in afternoon trading after Reuters reported that activist investor Ananym Capital was an lively investor demands changes in the corporate. The newly formed company, led by Charlie Penner and Alex Silver, believes, amongst other things, that the board needs to be restructured and costs reduced.

Henry Schein and other stocks on this space offer a vibrant spot in a sector that has largely struggled because the election. The Health Care Select Sector SPDR Fund (XLV) fell greater than 3% in November, heading in the right direction for its first three-month losing streak since last yr. In comparison, the width S&P 500 is up greater than 3% for the month.

Gordon Haskett's Bilson also identified that dental stocks were among the many few “spared” health-focused stocks as investors reacted to the announcement of Kennedy's nomination last week. Pharmaceutical firms were under pressure as Kennedy is seen as a vaccine skeptic, while processed food stocks slumped as traders prepared for increased scrutiny of so-called junk foods.

“It has led to widespread sales across the health care industry,” Bilson said of the choice to decide on Kennedy. “Drug manufacturers, contract research organizations and health insurers all felt the quake. Instead of stopping there, the damage spread to packaged foods. And on the advertising.”

While the market appears to be moving in light of Kennedy's nomination, Bilson said regulatory changes would likely take years to take effect. He also noted that drinking water needs to be under the jurisdiction of the Environmental Protection Agency relatively than Health and Human Services.

Anyone searching for a house today knows that there continues to be little or no on the market.

The real estate market is recovering from the leanest years in its history. The inventory of recent and existing homes is finally rising, but suddenly there’s something strange in regards to the numbers: The supply of newly built homes appears to be way too high.

However, these numbers are misleading because today's real estate market is experiencing unprecedented momentum that dates back to a different era in housing construction that dates back twenty years: the subprime mortgage boom.

All of for this reason real estate prices, which normally fall when supply is high, just keep rising.

According to the National Association of Home Builders (NAHB), there may be currently a 4.4-month supply of recent and existing homes on the market. Months supply is a standard calculation out there to measure how long it might take to sell all available homes at the present sales pace. A six-month supply is taken into account a balanced market between buyers and sellers.

Supply was already low in the beginning of this decade, but pandemic-related demand pushed it to record lows of just two months in early 2021. This shortage of homes on the market, combined with strong demand, pushed home prices up greater than 40% from pre-pandemic levels.

Now supply is finally beginning to rise again, however the increases are mostly in the brand new home market, not the present home market. In fact, there may be now a nine-month supply of newly built homes on the market, nearly 3 times as much as existing homes. Monthly supplies for brand new and old homes are frequently pretty close. According to the NAHB, recent homes now account for 30% of total inventory, about double their previous share.

“June 2022 saw the largest ever lead in new home months supply (9.9) over existing single-family home months supply (2.9),” wrote Robert Dietz, NAHB chief economist. “This disconnect makes clear that an assessment of current market inventory cannot simply look at existing or new home inventory in isolation.”

This unusual dynamic was triggered by each recent fluctuations in mortgage rates of interest and an unprecedented disaster within the housing market that began 20 years ago.

This housing market is more unique than another attributable to unique economic forces. First, there was an enormous increase in home sales, home construction and residential prices in 2005, fueled by a surge in subprime mortgage lending and a frenzy of trading in recent financial products backed by those mortgages.

All of that quickly collapsed, resulting in considered one of the worst foreclosure crises for the reason that Great Depression and triggering the Great Recession that followed. Single-family housing starts fell from a peak of 1.7 million units in 2005 to simply 430,000 in 2011. By 2012, recent homes represented only 6% of the overall supply on the market, and even by 2020, housing starts had not recovered to their historical average of about 1.1 million units. They stood at 990,000.

Then got here the Covid-19 pandemic. During that point, consumer demand soared and mortgage rates hit greater than a dozen record lows, so builders responded. Housing starts rose to 1.1 million in 2021. The Federal Reserve bailed out the economy, making homebuying significantly more cost-effective, and the brand new work-from-home culture had Americans moving like never before. Suddenly, supply was swept up in a tornado of demand.

The current strange supply gap between recent construction and existing homes can also be attributable to the rollercoaster ride of mortgage rates, which fell to historic lows in the beginning of the pandemic and rose to a 20-year high just two years later. Millions of borrowers refinanced on the lows and now don’t have any desire to maneuver because they’d need to trade a 3% or 4% rate of interest on their loans for the present rate of around 7%. This lock-in effect meant that recent supply has dried up.

It's also put builders in the motive force's seat. Builders had already ramped up production within the early years of the pandemic, with single-family home construction rising to over 1.1 million in 2021, in accordance with the U.S. Census, before falling again as mortgage rates soared. Builders were capable of lower mortgage rates to maintain sales high, but as of this May, they've been constructing at an annual rate of 992,000.

Resale listings improved barely this spring as mortgage rates declined barely, and lively listings in June were 16.5% higher than a 12 months earlier, in accordance with Redfin. However, a few of that increased supply was attributable to listings staying available on the market longer.

“The share of homes on the market for at least a month has increased year-over-year since March, when new listing growth accelerated, but buyer demand remained subdued, as it has since mortgage rates began rising in 2022,” a Redfin report said.

In the resale market, supply is thinnest within the $100,000 to $500,000 price range, in accordance with the National Association of Realtors, where nearly all of buyers are today, as higher mortgage rates prompt them to search for cheaper homes.

Interestingly, while supply is increasing in all price ranges, it’s increasing most within the cheaper price range. This signifies that there may be simply not enough. As quickly as houses come onto the market, also they are being signed into contract.

For example, there is just a 2.7-month supply of homes on the market between $100,000 and $250,000, but supply is up 19% from last 12 months. At the identical time, there may be a 4.2-month supply of homes priced over $1 million, but supply is up only 5% from last 12 months.

This explains why housing prices remain stubbornly high despite improved supply. According to CoreLogic, prices in May, probably the most recent reading, were 4.9% higher than they will probably be in May 2023. Gains have began to shrink barely, but not in every single place.

“In markets where inventories are well below pre-pandemic levels, such as the Northeast, this spring's sustained stronger home price increases are continuing,” said Selma Hepp, chief economist at CoreLogic.

“In addition, markets that are relatively more affordable, such as those in the Midwest, have seen healthy price growth this spring.”

Hepp points out that in Florida and Texas, where the provision of homes on the market is increasing comparatively strongly, prices are actually below the extent of a 12 months ago.

While analysts expect prices to ease within the second half of the 12 months and mortgage rates to fall, it stays to be seen whether rates will actually fall and whether the imbalance between supply and demand will allow prices to chill down. If mortgage rates do indeed fall, demand will definitely rise, putting much more pressure on supply and keeping prices high.

“Yes, inventories are rising and will continue to rise, especially as the effect of mortgage rate lock-in wears off in the coming quarters. But current inventories continue to support new construction and some price growth nationally,” Dietz added.